Search Results - Cathy Zhang
- Showing 1 - 7 results of 7
-
1
-
2
PEST Domain Mutations in Notch Receptors Comprise an Oncogenic Driver Segment in Triple-Negative Breast Cancer Sensitive to a γ-Secretase Inhibitor by Kai Wang, Qin Zhang, Danan Li, Keith A. Ching, Cathy Zhang, Xianxian Zheng, Mark Ozeck, Stephanie Shi, Xiaorong Li, Hui Wang, Paul A. Rejto, James G. Christensen, Peter Olson
Published 2015Artigo -
3
Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth by Brion W. Murray, Chuangxing Guo, Joseph Piraino, John Westwick, Cathy Zhang, Jane E. Lamerdin, Eleanor Dagostino, Daniel Knighton, Cho‐Ming Loi, Michael Zager, Eugenia Kraynov, Ian Popoff, James G. Christensen, Ricardo Martinez, Susan E. Kephart, Joseph Marakovits, Shannon Karlicek, Simon Bergqvist, Tod Smeal
Published 2010Artigo -
4
HIP1–ALK, A Novel ALK Fusion Variant that Responds to Crizotinib by Douglas D. Fang, Bin Zhang, Qingyang Gu, Maruja E. Lira, Qiang Xu, Hongye Sun, Maoxiang Qian, Weiqi Sheng, Mark Ozeck, Zhenxiong Wang, Cathy Zhang, Xinsheng Chen, Kevin X. Chen, Jian Li, Shu‐Hui Chen, James G. Christensen, Mao Mao, Chi-Chung Chan
Published 2014Artigo -
5
Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia by Manoj Kumar Kashyap, Carlos I. Amaya-Chanaga, Deepak Kumar, Brett H. Simmons, Nanni Huser, Yin Gu, Max Hallin, Kevin C. Lindquist, Rolla Yafawi, Michael Y. Choi, Amine Ale-Ali, Laura Z. Rassenti, Cathy Zhang, Shu‐Hui Liu, Tod Smeal, Valeria R. Fantin, Thomas J. Kipps, Flavia Pernasetti, Januario E. Castro
Published 2017Artigo -
6
A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies by Shu‐Hui Liu, Yin Gu, Bernadette Pascual, Zhengming Yan, Max Hallin, Cathy Zhang, Conglin Fan, Wenlian Wang, Justine L. Lam, Mary E. Spilker, Rolla Yafawi, Eileen Blasi, Brett H. Simmons, Nanni Huser, Wei-Hsien Ho, Kevin C. Lindquist, Thomas-Toan Tran, Jyothirmayee Kudaravalli, Jing-Tyan Ma, Gretchen S. Jimenez, Ishita Barman, Colleen Brown, Sherman M. Chin, Maria José Costa, David L. Shelton, Tod Smeal, Valeria R. Fantin, Flavia Pernasetti
Published 2017Artigo -
7
CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety by Cynthia L. Palmer, Britton Boras, Bernadette Pascual, Na Li, Danan Li, Scott J. Garza, Nanni Huser, Jing Yuan, Julie Cianfrogna, Tae Sung, Elizabeth A. McMillan, Na Wei, Jason Carmody, Augustine Kang, Seth Darensburg, Tiana Dodd, James V. Oakley, James Solowiej, Lisa Nguyen, Suvi T. M. Orr, Ping Chen, Eric W. Johnson, Xiu Yu, Wade Diehl, Gary M. Gallego, Mehran Jalaie, Rose Ann Ferre, Sujin Cho-Schultz, Hong Shen, Judith G. Deal, Qin Zhang, Timothy R. Baffi, Meirong Xu, Whijae Roh, Jennifer Lapira-Miller, Jérôme Goudeau, Yanke Yu, Rajat Gupta, Kimberly H. Kim, Stephen G. Dann, Zhengyan Kan, John C. Kath, Sajiv K. Nair, Nichol Miller, Brion W. Murray, Andrew R. Nager, Casey L. Quinlan, Matthew D. Petroski, Cathy Zhang, Aida Sacaan, Todd VanArsdale, Lars Anders
Published 2025Artigo
Search Tools:
Related Subjects
Cancer research
Medicine
Biology
Antibody
CXCR4
Chemokine
Effector
Gene
Genetics
Immunology
Internal medicine
Oncology
Pharmacology
Receptor
2019-20 coronavirus outbreak
ALK inhibitor
Anaplastic lymphoma kinase
Antagonist
Biochemistry
Breast cancer
Business
CXCR4 antagonist
Cancer
Cell
Cell biology
Cell cycle
Cell growth
Chemistry
Chronic lymphocytic leukemia
Computer network